Author： Ginsberg Lawrence
Publisher： Informa Healthcare
ISSN： 1040-1237
Source： Annals of Clinical Psychiatry (after Jan 1, 2004), Vol.18, Iss.1, 2006-03, pp. : 23-26
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Background. Predictors of response to psychoactive drugs are valuable in providing practical guidance and in optimizing a treatment regimen. Here we used linear regression analysis to identify treatment-specific predictors of response to therapy with beaded extended-release carbamazepine capsules (CBZ-ERC) (Shire, Wayne, PA, USA) in 600 outpatients with bipolar disorder. Methods. Data were obtained from medical charts of subjects who received CBZ-ERC in a private practice setting. Illness severity and improvement were assessed using the Clinical Global Impression–Severity (CGI-S) and Clinical Global Impression–Improvement (CGI-I) scales. Results. We found that increasing baseline CGI-S scores correlated with lower CGI-I scores (R 2 = 0.01, p = 0.009); that is, the higher the baseline CGI-S score, the greater the expected degree of improvement. There was also a correlation between increasing CBZ-ERC dose and improvement in CGI-I scores (R 2 = 0.02; p = 0.0004). Moreover, we found that increasing carbamazepine (CBZ) blood concentration correlated with decreases in CGI-I scores (R 2 = 0.12; p = 0.025), and that there was a correlation between higher total daily CBZ-ERC dose in mg/kg of body weight and decreases in CGI-I scores (R 2 = 0.01; p = 0.038). Conclusions. These findings suggest that bipolar patients with more severe baseline symptoms, on higher CBZ-ERC doses, and with higher CBZ blood levels were more likely to respond to CBZ-ERC treatment.
Related content
Access to resources
Recommend
